Opening of the production facilities for manufacture of APIs, soft and solid dosage forms, and injectable forms.
The beginning of the partnership with Solvay Pharma (currently, Abbott).
Assignment of the International Non-proprietary Name - Azoximer bromide for Polyoxidonium® by WHO.
The State Prize of the Russian Federation awarded to the team of creators and developers led by Proffessor A.V. Nekrasov for the creation of innovative medicines Polyoxidonium® and Grippol® and for their implementation in healthcare practice.
Obtaining USA, Indian, South Korean and EU patents for Longidaza®.
Production expansion: opening of the 4th line of production for manufacturing of injectable dosage forms, start of construction of new biotechnological complex.
The beginning of cooperation with ISU ABXIS (South Korea) to localize production of medicine for orphan therapy — Fabry disease.
Сhange in the composition of shareholders — Interros Group left the membership of the company.
Large-scale clinical trials program of Polyoxidonium® and Longidaza® in the prevention and treatment of COVID-19.
Project for the development and manufacture of the vaccine against COVID-19 — Convidecia — in cooperation with CanSino Biologics Inc.
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.
This site contains information for medical and pharmaceutical professionals. To view the content, please, confirm that you have the appropriate qualifications.